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Abstract
Background: Reactive oxygen species (ROS) production via NADPH oxidase (NOX) contributes to various types of
cancer progression. In the present research, we examined the pathobiological role of NADPH oxidase (NOX)4-
mediated generation of reactive oxygen species (ROS) in urothelial carcinoma (UC) of the urinary bladder, and
demonstrated the utility of ROS labeling in urine cytology.
Methods: NOX4 gene was silenced in vivo and in vitro by NOX4 siRNA transfection with or without atlocollagen.
Cell cycle and measurement of ROS were analyzed by flowcytometry. Orthotopic implantation animal model was
used in vivo experiment. NOX4 expression in urothelial carcinoma cells was observed by immunohistochemical
analysis using surgical specimens of human bladder cancer. Urine cytology was performed after treatment with
ROS detection reagents in addition to Papanicolaou staining.
Results: NOX4 was overexpressed in several UC cell lines and the NOX inhibitor, diphenylene iodonium reduced
intracellular ROS and induced p16-dependent cell cycle arrest at the G1 phase. Moreover, silencing of NOX4 by
siRNA significantly reduced cancer cell growth in vivo as assessed in an orthotopic mouse model.
Immunohistochemistry demonstrated high expression of NOX4 in low grade/non-invasive and high grade/invasive
UC including precancerous lesions such as dysplasia but not in normal urothelium. Then, we assessed the
usefulness of cytological analysis of ROS producing cells in urine (ROS-C). Urine samples obtained from UC cases
and normal controls were treated with fluorescent reagents labeling the hydrogen peroxide/superoxide anion and
cytological atypia of ROS positive cells were analyzed. As a result, the sensitivity for detection of low grade, non-
invasive UC was greatly increased (35% in conventional cytology (C-C) vs. 75% in ROS-C), and the specificity was
95%. Through ROS-C, we observed robust improvement in the accuracy of follow-up urine cytology for cases with
previously diagnosed UC, especially in those with low grade/non-invasive cancer recurrence (0% in C-C vs. 64% in
ROS-C).
Conclusions: This is the first report demonstrating that ROS generation through NOX4 contributes to an early step
of urothelial carcinogenesis and cancer cell survival. In addition, cytology using ROS labeling could be a useful
diagnostic tool in human bladder cancer.
Background
Urinary bladder cancer is the seventh most common
cancer in the world, with over 10,000 new cases diag-
nosed annually in Japan. At initial diagnosis, 75% of
cases present as superficial (pTa and pT1) tumors and
have a good clinical outcome (5-year survival rates
ranging from 88% to 98%). However, approximately 50%
of patients with non-muscle invasive tumors will experi-
ence disease recurrence within 4 years of their initial
diagnosis, and 11% will progress to the invasive pheno-
type [1]. The remaining 25% of cases present with mus-
cle invasive bladder cancer and have a poor prognosis
(5-year survival rate ranging from 46% to 63%) [2,3].
Other factors that affect the survival of bladder cancer
patients include tumor grade, morphological features,
and the presence of lymphovascular invasion or node
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cancer have been recognized; for example, some reports
described an adverse outcome for urothelial carcinomas
with squamous, glandular, or trophoblastic differentia-
tion, or nested variants, or invasive micropapillary var-
iants and so on [4]. In 2004, the World Health
Organization published a classification system for
tumors of the urinary system with criteria for patient
risk stratification. Specific variants have a distinct thera-
peutic strategy in addition to the conventional clinical
management of urothelial carcinoma [5,6].
Overall, not only is early and accurate histological
diagnosis and staging important but long-term surveil-
lance is also required for the successful management of
human bladder cancer. The current gold standards for
diagnosis and surveillance are conventional white light
cystoscopy and urine-based cytology. The former
enables direct visualization of tumors and histopatholo-
gical analysis from biopsy samples. However, cystoscopy
is a painful procedure that is associated with iatrogenic
risk; moreover, small areas of flat tumors as well as car-
cinoma in situ can easily be missed [7]. In contrast,
u r i n e - b a s e dc y t o l o g yi sas i m p l ea n dc o s t - e f f e c t i v ep r o -
cedure that can detect tumors with high specificity (78-
100%) whether they are visualized or not. The sensitivity
is low (12.2-84.6%), however, especially for low-grade
tumors, which are the most prevalent and subject to
considerable interobserver variability [8]. If we can,
therefore, identify a solution that compensates for these
disadvantages, cytology will be one of the simplest and
most reliable diagnostic and screening tools available
with high reproducibility.
Reactive oxygen species (ROS) are implicated in both
stimulation and inhibition of cell proliferation, apopto-
sis, and cell senescence [9,10]. ROS trigger genetic pro-
grams associated with transformation, resulting in the
alteration of genes by manipulating the cell cycle and
signal transduction pathways [11]. Similarly, generation
of oxygen radicals is increased in Ras-transformed fibro-
blasts [12] and antioxidants can block DNA synthesis,
suggesting involvement of ROS in mitogenic signaling in
the course of neoplastic transformation. NADPH oxi-
dase (NOX) is one of the major sources of cellular ROS
[13]. NOX enzymes are the structural homologues of
phagocytic NOX (gp91phox/NOX2) and consist of both
single (NOX1-NOX5) and dual oxidases (DuOX1 and
DuOX2). Emerging evidence suggests that low levels of
ROS generated by NOX enzymes act as mediators in
inflammation, apoptosis, cell growth, and angiogenesis
in various human cancers. Recently, we identified gen-
eration of intracellular hydrogen peroxide by NOX1 as a
major downstream signal for a novel human AlkB
homologue, ALKBH-8, that contributes to cell survival
by enhancing resistance to apoptosis in human
urothelial carcinoma cells, both in vitro and in vivo [14].
Since hALKBH8 and NOX1 are immunohistochemically
overexpressed in high-grade invasive urothelial carcino-
mas but not in low-grade non-invasive phenotypes, ROS
generation through NOX1 plays an important role in
the progression of bladder cancer, but not in carcino-
genesis or the early stages of cancer development.
In the present study, we show that NOX4 maintained
intracellular generationo fR O Si nb o t hh i g ha n dl o w
grade and superficial and invasive urothelial carcinoma
cells and contributes to cancer cell survival, using in
vitro and in vivo experiments and clinicopathological
analyses. Moreover, fluorescent labeling of ROS-positive
cells in voided urine samples made easy detection of
exfoliated cancer cells possible, resulting in improved
sensitivity of urine cytology in bladder cancers.
Methods
Cell culture, plasmids, and chemicals
The human urothelial carcinoma cell lines, T24,
UMUC6, and KK47, were purchased from American
Type Culture Collection (Manassas, VA) and cultured in
RPMI supplemented with 10% fetal bovine serum. We
purchased the anti-p16 antibody from Cell Signaling
(MA); anti-actin antibody from Santa Cruz Biotech. Inc.
(CA); anti-NOX4 antibody from Abcam (UK) and
diphenyleneiodonium (DPI) from Wako (Osaka, Japan).
Preparation of cell lysates and western blotting analysis
We resolved the cell lysates in sodium dodecyl sulfate
(SDS)-polyacrylamide gels and transferred them to poly-
vinylidene difluoride membranes (Millipore, Ltd.), which
were then blocked in 5% skim milk at room temperature
for 1 h. We incubated the membranes with the indi-
cated primary antibody for 1 h and then incubated with
horseradish peroxidase-conjugated anti-mouse or anti-
rabbit IgG (Amersham Pharmacia Biotech). We detected
peroxidase activity on X-ray films by using an enhanced
chemiluminescence detection system.
Reverse transcription PCR
Using the OneStep reverse transcription polymerase
chain reaction (RT-PCR) kit (QIAGEN), we extracted
total RNA by using the Trizol reagent and subjected it
to RT-PCR. The PCR conditions were 95°C for 30 s, 55-
60°C for 30 s, and 72°C for 1 min through a total of 30
cycles. The PCR primer sequences for NOX2 were 5’-
GGGCTGTTCAATGCTTGTGGCT-3’ (sense) and 5’-
ACATCTTTCTCCTCATCATGGTGC-3’(antisense).
The primers for NOX3 were 5’-ATGAACACCTCTGG
GGTCAGCTGA-3’ (sense) and 5’-GGATCGGAGT-
CACTCCCTTCGCTG-3’ (antisense). The primers for
NOX4 were 5’5’-CTCAGCGGAATCAATCAGCTGTG-
3’ (sense) and 5’- AGAGGAACACGACAATCAG
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ATCAAGCGGCCCCCTTTTTTTCAC-3’(sense) and 5’-
CTCATTGTCACACTCCTCGACAGC-3’ (antisense).
The primers used for actin were 5’-ATGGGTCAGAAG-
GATTCCTATGT-3’ (sense) and 5’-GAAGGTCTCAAA-
CATGATCTGGG-3’ (antisense).
Identification and measurement of ROS
We assessed the production of intracellular superoxide
anion (O2
-)a n dH 2O2 with dihydroethidium (DHE,
Wako, Osaka, Japan) and 5,6-chloromethyl-2’,7’-dichlor-
odihydrofluorescein diacetate (CM-DCF-DA, Wako),
respectively. Cells were incubated with 5 μMD H Eo r
DCF-DA solution for 30 min at 37°C. Excess DHE or
DCF-DA was washed, and then superoxide anion (O2-)
or hydrogen peroxide (H2O2) formation in the cells was
visualized using a Leica CTR6000 photomicroscope and
measured by flow cytometry.
Transfection of NOX4 siRNA
For our transfection analyses, 10
6 cells from each
urothelial carcinoma cell line were seeded in 6-cm dish
plates and transfected with either 100 nM of control
RNA (Santa Cruz) or with the small interfering RNA
(siRNA) of NOX4. Transfections were carried out using
the Lipofectamine system (Invitrogen) in accordance
with the manufacturer’s protocol. The human NOX4
siRNA duplexes, generated with 3’-dTdT overhangs and
prepared by QIAGEN (Hs-NOX4-1-HP siRNA), were
chosen against the DNA target sequences as follows: 5’-
TCCATTTGCATCAATACTCAA-3’.
Cell proliferation assay
Cells were stimulated with various reagents for a given
period, after which methanethiosulfonate (MTS) reagent
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulphonyl)-2H-tetrazolium, inner salt; Pro-
mega, Tokyo, Japan) was added. After a 3-h incubation
period, optical absorbance at 490 nm was measured
using a microplate reader. Cell viability was expressed as
a mean percentage of the standard deviations of absor-
bance before and after treatment with various reagents.
All experiments were performed in triplicate.
Tissue samples and immunohistochemistry
We obtained specimens of human urinary bladder can-
cers diagnosed as urothelial carcinomas (n = 82) from
patients undergoing transurethral resection or radical
cystectomy without previous history of radiation or che-
motherapy at the Nara Medical University Hospital.
Clinicopathologic data of the cases were reviewed by 2
urological pathologists (K.S. and N.K., Department of
Pathology, Nara Medical University Hospital) and sum-
marized in Table 1. Normal or atypical urothelial tissue
samples found in patients with or without severe cystitis
(induced by intravesical stones, long-lasting catheteriza-
tion, etc.) were obtained from autopsy cases (n = 17 for
each). The study was approved by the institutional
research board of Nara Medical University, and
informed consent was obtained from all patients. Tumor
stage and grade were noted at the time of diagnosis
before the collection of specimens. We followed the
same tissue fixation and processing procedure as
described in a previous report [15-17]. After deparaffini-
zation, the sections were heated for 5 min in 10 mM of
sodium citrate buffer (pH 6.0) in a pressure cooker. The
sections were then incubated overnight at 4°C with the
indicated antibodies. The reactions were visualized using
the Histofine streptavidin-biotin-peroxidase complex
(SAB-PO) kit with diaminobenzidine as the chromogen
(Nichirei, Tokyo, Japan) and hematoxylin counterstain-
ing. The percentage of cells positive for NOX4 were
expressed per 1,000 cells examined.
Conventional and ROS-labeled cytological analyses
We obtained 50 voided urine samples and histological
specimens from bladder cancer patients without pre-
vious bladder cancer (samples were submitted at the
initial diagnosis) and 80 cases without neoplasia (cystitis,
bladder stone, chronic kidney disease etc) (Table 2). In
addition, 62 follow-up urine samples from patients with
previous bladder cancer that were negative (non-recur-
rence; n = 34) or positive (first to third recurrence; n =
28) were available, in positive cases, and histological spe-
cimens were submitted as well (Table 3). In all follow-
up cases, the diagnosis was made using histology if a
tumor or a questionable lesion (such as redness, erosion,
or papillary growing lesions) was found. Voided urine
specimens were collected and incubated with 10 μM
DHE and CM-DCFDA for detection of superoxide
anion (O2-) and hydrogen peroxide in serum-free RPMI
medium for 30 min at 37°C in the dark. After reaction,
the cells were washed with phosphate-buffered saline
Table 1 Characteristics of urothelial carcinomas for
immunohistochemistry
Age (years) 65 (54-83)
Gender (M:F) 61:21
Stage
pTa 19
pT1 22
≧pT2 14
pTis 27
Grade
Low grade 25
High grade 57
Total 82
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Papanicolaou-stained ThinPrep or Cytospin slides were
prepared. The diagnosis using Papanicolaou stain sam-
ples was made on the basis of 3 categories (negative,
suspicious, and positive) by a team of 2 cytopathologists
(K.S. and N.K.). Carcinoma was highly suspected, but
the number of cytomorphologic changes of the atypical
cells was not enough to make a definitive positive diag-
nosis, for example, due to therapy-mediated cellular
degeneration. At the same time, urine samples were
examined through a fluorescein isothiocyanate (FITC)-
Texas Red (Tx2) filter by fluorescence microscopy.
Results were expressed as positive if more than 20 dou-
ble-positive cells with features of cellular atypia were
found in each sample. Once a positive diagnosis was
made, the remaining specimen was incubated with the
ROS scavenger, N-acetyl-L-cysteine, and we checked
whether fluorescent reactivity was lost. If fluorescence
was not significantly reduced or lost, results were
expressed as invalid to preclude autofluorescence.
Inflammatory cells also produced ROS, but the level was
much lower than that for urothelial carcinoma cells, and
these cells were morphologically excluded with Papani-
colaou staining. The size of tumor cells was slightly
decreased after incubation with ROS detecting reagents
in the cell culture medium for 30 min at 37°C. However,
cellular atypia, including hyperchromasia, enlarged
nucleoli, irregular shape and so on, was not significantly
modified; therefore, there was no problem with diagno-
sis by conventional cytology.
Orthotropic implantation animal model
Animal experiments were approved by the institutional
animal care and use committee at Nara Medical Univer-
sity. Eight week-old female nude mice were maintained
on a daily 12-h cycle of light and dark and were fed stan-
dard diet and water ad libidum [14,18]. The mice were
purchased from CLEA (Tokyo, Japan) and maintained
with the CLEA Rodent diet http://www.clea-japan.com/
Feed/cl2.html. Fourteen days after transcatheter inocula-
tion of 5 × 10
7 KU-7 cells with or without green fluores-
cent protein (GFP) expression in the urinary bladder, the
mice were randomized into either control (control RNA
+ atelocollagen, n = 10) or NOX4 knockdown (NOX4
siRNA + atelocollagen, n = 8) treatment groups and
received a single intravesical treatment instillation that
was retained for 1 h by purse-string suture. The mice
were sacrificed 14 days after treatment, and the bladders
were removed, splayed open on filter paper, and fixed in
10% neutral buffered formalin, or tumor cells were
homogenized and treated with CM-DCFDA or DHE, fol-
lowed by analysis of ROS generation by flow cytometry.
Image analysis
The tumor burden was determined by analyzing images of
GFP fluorescence from tumor cells on flat formalin-fixed
bladders captured by a fluorescent stereomicroscope.
Image analysis was done with Image J public domain soft-
ware available through the National Institute of Health.
Table 2 Characteristics of patients with initial diagnosis
of urothelial carcinoma
Age (years) 70 (44-96)
Gender (M:F) 40:10
Stage
pTa 10
pT1 6
≧pT2 6
pTis 8
Grade
Low grade 24
High grade 26
Total 50
Table 3 Comparison of conventional cytology with ROS cytology (initially diagnosed urothelial carcinomas)
Conventional cytology ROS cytology
Urothelial carcinoma Positive Suspicious Negative Sensitivity Positive Negative Sensitivity
Low grade(n = 24) 9 7 8 35% 18 6 75%
High grade(n = 26) 21 1 2 88% 22 2 92%
Non-invasive papillary 10 8 8 39% 20 6 77%
(n = 26)
Superficially invasive 6 1 0 86% 6 1 86%
(n = 7)
Deep invasive 6 0 0 100% 6 0 100%
(n = 6)
Carcinoma in situ 8 0 1 89% 8 1 89%
(n = 10)
Specificity Specificity
Negative(n = 80) 6 13 72 90% 4 76 95%
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ments. The mice were then sacrificed, and the bladders
were excised and fixed for histologic examination by
hematoxylin and eosin stain and immunohistochemistry.
Statistical analysis
Data were statistically analyzed using the student’s t-test
or non-parametric analysis Kruskal-Wallis test [14,18].
The results were considered significant if P value was
less than 0.05.
Results
NOX4-mediated generation of ROS affects urothelial
carcinoma cell survival in vitro
At the beginning of the experiment, the expression of
NOX family members, apart from NOX1, was examined
in the human urothelial carcinoma cell lines T24,
UMUC6, and KK47. RT-PCR analysis showed that
NOX4 was highly expressed in all 3 cell lines. ROS,
including the radical superoxide anion and non-radical
hydrogen peroxide, were constitutively generated as
examined by fluorescent microscopy or flow cytometry
using DHE and CM-DCF-DA, but ROS levels signifi-
cantly declined following NOX4 siRNA transfection
(Figures 1A and 1B). The same finding was observed in
the UMUC6 and KK47 cell lines (data not shown).
Moreover, NOX4 knockdown by siRNA transfection
suppressed cell growth via p16 induction and cell cycle
arrest at the G1 phase in the T24 and UMUC6 cell lines
(Figure 1C)). Similarly, treatment with the NOX inhibi-
tor, diphenylene iodonium (DPI), induced p16 and cell
cycle arrest at the G1 phase, resulting in inhibition of
Figure 1 The role of NOX4-mediated ROS generation in human bladder cancer cells. (A) RNA was extracted from human urothelial
carcinoma cell lines, T24, UMUC6 and KK47, then mRNA levels of NOX 2, 3, 4 and 5 were analyzed by RT-PCR. mRNA expression of actin was
used for (B) T24 cells were treated by ROS detecting fluorescence reagents, CM-DCFDA and DHE, and ROS generation was assessed by
fluorescence microscopy (left panel). T24 cells were tarnsfected by NOX4 siRNA at 100 nM and control RNA. After 72 h inoculation, cells were
treated with CM-DCFDA and DHE, then intracellular ROS levels were analyzed by flowcytometer as described. Solid black indicates negative
control (treated with DMSO). (C) T24 and UMUC6 cells were tarnsfected by NOX4 siRNA at 100 nM and control RNA. After 72 h inoculation, MTS
assay, flowcytometric analysis using propidium iodide or western blotting using anti-NOX4, p16 antibody was performed. Actin was used for
protein or mRNA expression of housekeeping gene throughout the experiments. Each value is the mean ± SE.
Shimada et al. BMC Urology 2011, 11:22
http://www.biomedcentral.com/1471-2490/11/22
Page 5 of 12cancer cell growth in T24 and UMUC6 cells (Figure 2).
Treatment with ROS scavengers, such as N-acetyl-L-
cysteine, induced cell cycle arrest as expected and inhib-
ited the rate of cell growth (data not shown).
NOX4 gene silencing reduced tumor volume in
orthotopic implantation model
We examined the role of NOX4 in bladder cancer
development in vivo. Using a KU7 cell line stably over-
expressing GFP, we previously established GFP image
analysis in this system, so that tumor growth and
treatment response can be quickly measured [14]. As
s h o w ni nF i g u r e s3 Aa n d3 B ,N O X 4d o w n - r e g u l a t i o n
(knockdown efficacy was 60-70% as assessed by wes-
tern blotting) by instillation of siRNA combined with
atelocollagen produced a significant decrease in the
tumor area in the orthotropic implantation mouse
experiment. Flow cytometric analysis indicated that
CM-DCFDA and DHE double-positive populations in
implanted tumor cells were strongly reduced by NOX4
gene silencing, which was consistent with in vitro
experimental data (Figure 3C). These results clearly
show that NOX4-dependent ROS generation plays an
important role in the growth of urothelial carcinoma
cells both in vitro and in vivo.
NOX-4 is expressed in urothelial carcinoma but not in
normal urothelium of human urinary bladder
We performed immunohistochemistry for NOX4 in sur-
gical specimens of human bladder cancer and normal
tissue derived from autopsy samples (Table 1). Figures
4A-a, b, c, d, e and 4f clearly demonstrate that NOX4 is
seldom expressed in normal urothelium, nor is it
expressed in reactive atypia (mostly due to chronic
inflammation/denudation), but was overexpressed in low
or high-grade and non-invasive or invasive urothelial
carcinoma cells, including carcinoma in situ (CIS). The
NOX4 expression level was not correlated to pathologi-
cal parameters such as grade, stage, and tumor size (Fig-
ure 4B). Interestingly, the immunopositive findings for
NOX4 for the precancerous lesion dysplasia were statis-
tically higher than those for normal urothelium.
Figure 2 NOX inhibition induced cell cycle arrest, resulting in suppression of cancer cell growth. T24 and UMUC6 cells were treated with
DPI at the indicated concentrations for 48 h, then MTS assay(A), flowcytometric cell cycle analysis using propidium iodide (B) or western blotting
using anti-p16 antibody (C) was performed. Each value is the mean ± SE.
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cancer (initially diagnosed cases)
Since the NOX4-ROS signal was strongly amplified in
urothelial carcinoma cells, unlike in normal urothelial
cells, we attempted to clarify the usefulness of ROS
labeling in cytological diagnosis. Voided urine samples
were collected from 50 different patients initially diag-
nosed with urothelial carcinomas of the urinary bladder
(no previous history of bladder tumors) (Table 2) and
80 normal controls diagnosed with chronic cystitis, urin-
ary tract stones or chronic pyelonephritis. Cells in urine
samples were treated with the ROS-detecting fluorescent
reagents, DCF-DA and DHE, and then routine Papani-
colaou staining was performed. Initially, conventional
cytological diagnosis (conventional cytology, C-C) was
made and divided into 3 categories: negative, suspicious
and positive. Then, we extracted ROS fluorescence-
positive cells and examined whether they presented
cytological atypia or whether cytologically atypical cells
exhibit ROS generation under bright/fluorescent fields
(termed ROS cytology, ROS-C). If the number of ROS-
positive cells with significant atypia exceeded 20 cells,
we judged it as a “positive finding of ROS-C.” Figure 5A
indicates typical positive cases: malignant cytological
findings were observed by the Papanicolaou staining
method under bright field microscopy; moreover, these
cells were confirmed to generate superoxide anion and
hydrogen peroxide under the fluorescence field. The his-
tological diagnosis from transurethral resection of blad-
der cancer was high-grade, superficially invasive
urothelial carcinoma (pT1). Figure 5B demonstrates the
usefulness of ROS-C: atypical, small urothelial cells were
detected by the Papanicolaou stain, but the number of
atypical cell foci was too small with little atypia, which
Figure 3 Intravesical injection of NOX4 siRNA inhibits tumor growth in vivo in the mouse orthotopic bladder cancer implant model.
(A) Upper panel indicates brief experimental protocol. 14 days after KU7/GFP cells were transplanted into the mouse bladder, atelocollagen with
either NOX4 siRNA or control RNA was transurethrally instilled into the bladder lumen. Urinary bladders were resected 14 d post-instillation, and
in situ images captured under fluorescent light (lower panel). (B) indicates growth suppression in lesions treated with NOX4 siRNA/atelocollagen
and control RNA/atelocollagen was compared in terms of tumor area measured by GFP expression and histologic analysis. Columns, mean; bars,
SE. Bladder cancer samples were resected, lysed, and expression of NOX4 was determined by Western blot analysis. (C) Bladder cancer samples
derived from control and siRNA of NOX4 treatments animals were homogenized and cells were stained by CM-DCFDA and DHE. Then,
flowcytometric analysis was performed to determine the level of intracellular hydrogen peroxide/superoxide anion.
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“suspicious” was made. In contrast, the diagnosis by
ROS-C was “negative” because we could not detect
intracellular ROS production. Transurethral biopsy
revealed no malignant denuding cystitis. As shown in
Table 3, the sensitivities of ROS-C for low grade and
non-invasive urothelial carcinomas were higher than
those for C-C (75% and 77% vs. 35% and 39%, respec-
tively) (P < 0.01), whereas there were no statistical dif-
ferences for high-grade phenotypes between C-C and
ROS-C (88% vs. 92%); the sensitivities for superficially
or deeply invasive carcinomas and CIS were similar.
Both C-C and ROS-C revealed high values for specificity
(90% vs. 95%, no statistically significant difference). The
positive predictive value (PPV) was 90.9% and negative
predictive value (NPV) was 89.4%. Thus, ROS labeling
together with C-C might improve accuracy by increasing
the sensitivity for detecting bladder cancer, especially
with low grade, non-invasive phenotypes. All 15 cases
diagnosed as “suspicious” by C-C underwent cystoscopy
examination. Of these, 10 cases were low-grade urothe-
lial carcinomas and the others had normal urothelium
featuring denuding cystitis etc. Interestingly, ROS-C had
high sensitivity and specificity for cytologically “suspi-
cious” cases at 90% and 85%, respectively.
The use of ROS labeling in urine cytology for bladder
cancer (follow-up cases with previous history of urothelial
carcinomas)
Degeneration of urothelial cells would complicate cyto-
logical diagnosis even further in follow-up urine cytol-
ogy after surgery and/or immunotherapy (such as
Bacille de Calmette et Guérin (BCG) therapy, etc) for
bladder cancer. We attempted to clarify the usefulness
of ROS-C in follow-up urine cytology of bladder cancer.
The characteristics of patients with a history of urinary
bladder cancer are listed in Table 4. All patients had at
least 1 follow-up cytoscopy examination after C-C and
ROS-C, with a mean follow-up period of 4.7 months. As
shown in Table 5, both the sensitivity and specificity of
C-C at follow-up, particularly in cases with low-grade
and non-invasive carcinoma recurrence were markedly
decreased compared to those for cases initially diag-
nosed with urothelial carcinomas (low grade, 0% vs.
Figure 4 Immunohistochemical analysis of NOX4. Immunohistochemistry for NOX4 expression (A). The percentage of immunopositive cells
was calculated per 1,000 cells/high-power field (B). Each value is the mean ± SE.
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ity of C-C was very low even in cases with high-grade
and invasive carcinomas or CIS (high grade, 57%; inva-
sive carcinoma/carcinoma in situ, 47%). The sensitivities
of ROS-C for low-grade and non-invasive carcinomas
were 64% and 69%, respectively, which were statistically
higher than those of C-C for cases initially diagnosed as
urothelial carcinomas. The specificity of ROS-C was
97%, higher than that of C-C, which was 79% (P < 0.05).
Thus, cytomorphological analysis of ROS-positive cells
might be a reliable tool to improve the sensitivity of
urine cytology with high specificity. The present data
demonstrating zero sensitivity of urine cytology in low-
grade urothelial carcinomas partly resulted from the
small sample size. More data using adequate samples
should be collected for definite conclusions. The 14
cases cytologically diagnosed as ‘suspicious’ consisted of
7 cancer cases (2 were high-grade and 5 were low-grade
carcinomas) and the remaining 7 cases featured normal
urothelium, including post-BCG granulomatous cystitis.
The sensitivities of ROS-C for low and high-grade
urothelial carcinomas were 60% and 100%, respectively
for these “suspicious” cases, whereas specificity was
100%. Thus, ROS-C could determine whether cases
diagnosed as “suspicious” by C-C are truly positive or
negative.
Discussion
This is the first study showing that the NOX4-ROS sig-
nal contributes to the survival of human urothelial carci-
noma cells via progression of the G1/S transition. This
study also shows the practical use of ROS labeling in
Figure 5 Representative data of ROS urine cytology. (A) Atypical urothelial cell cluster was found under bright field, and these cells were
reactive to CM-DCFDA and DHE as determined under fluorescence filed (C-C is poitive and ROS-C is positive). Histological examination of
bladder tumors (H&E) revealed superficially invasive/high grade urothelial carcinoma (pT1). (B) Cluster of atypical small sized urothelial cells were
found under bright field, but intracellular ROS was not determined (C-C is ‘suspicious’ but ROS-C is negative). Histology of bladder specimen
(H&E) revealed denuding cystitis without malignant findings.
Table 4 Characteristics of follow-up cases after urothelial
carcinoma
Age (years) 73.1 (54-90)
Gender (M:F) 52:10
Negative 34
Positive 28
Stage
pTa 13
pT1 6
≧pT2 3
pTis 6
Grade
Low grade 14
High grade 14
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Page 9 of 12urinary cytology. Previously, we showed that a novel iso-
form of the DNA repair enzyme ALKBH, ALKBH-8,
contributes to progression of urothelial carcinoma cells
via NOX1-ROS signal-mediated resistance to apoptosis
induction [14]. Although ROS was produced in cancer
cells irrespective of pathological grade or stage, immu-
nohistochemistry showed high expression of NOX1 pro-
teins in high-grade, superficially, and deeply invasive
carcinomas (pT1 and > pT2), as well as in carcinoma in
situ, but not in low-grade and non-invasive phenotypes
( p T a ) .T h ep r e s e n ts t u d yu n c o v e r e dk e yd a t af o rt h e
resolution of this problem and provided a novel
mechanism involved in the development of bladder can-
cer: NOX4 was highly expressed in near-equivalent
levels in low and high grade or non-invasive and inva-
sive urothelial carcinomas, including dysplasia, but not
in normal urothelium. Moreover, NOX4 silencing
reduced ROS generation and suppressed cancer cell
growth via p16-dependent cell cycle arrest at the G1
phase, both in vitro and in vivo. These data indicate
that NOX4-mediated ROS generation contributes to an
early step in urothelial carcinogenesis and cancer cell
survival. In addition to NOX4, NOX1-mediated
enhancement of ROS generation might result in bladder
cancer cells of a more aggressive phenotype. Dysplasia
represents an early morphologic manifestation of pro-
gressive alteration between normal urothelium and car-
cinoma in situ, and clinicians must be attentive to the
clinical development. In contrast to CIS, clinical therapy
is not directly indicated for dysplasia. Therefore, pathol-
ogists should differentiate dysplasia from other flat aty-
pical urothelial lesions. There have been a number of
reports regarding molecular markers that enable accu-
rate differential diagnosis of flat atypical urothelial
lesions. CK20 and CD44 are the most useful markers
for distinguishing atypia of unknown significance (AUS)
from dysplasia (for example, CK20 expression is usually
limited to the umbrella cells but is expressed in the dee-
per mucosal layer in AUS) and p53 immunostains typi-
cally highlight the dysplastic cells [19-22]. However,
Murata et al. [19] demonstrated that molecular and
immunohistochemical analyses, including fluorescence
in situ hybridization (FISH), to detect expression of the
high molecular weight cytokeratin, Ki-67 and p53 can
discriminate between neoplastic and non-neoplastic
lesions. However, they cannot reliably resolve the diag-
nostic variation of flat intraepithelial lesions. Immuno-
histochemical analysis of NOX4, in addition to these
markers, will enable differential diagnosis of dysplasia.
NOX4 knockdown was expected to have no significant
effects on NOX1 expression but ROS levels were
strongly decreased, and the same phenomenon was also
observed in a NOX1 knockdown experiment (data not
shown). Therefore, in addition to NOX1, NOX4 is
required for the maintenance of intracellular ROS in
urothelial carcinoma cells. NOX4 should therefore be
the target molecule in bladder cancer treatment. Since
the expression of NOX4 was relatively high not only in
urothelial carcinoma cells but also in dysplasia as pre-
cancerous lesions, we hope to develop prophylaxis
against bladder cancer occurrence and recurrence with a
new strategy focusing on the NOX4-ROS signal. Various
studies have been carried out on the role of NOX4 in
pancreatic cancer progression. Mochizuki et al. demon-
strated inhibition of NOX4 activates apoptosis via the
Akt/apoptosis signal-regulating kinase 1 pathway in pan-
creatic cancer PANC-1 cells [20], but apoptosis was not
observed in urothelial carcinoma cells by NOX4 knock-
down, unlike in NOX1 gene silencing [14]. The biologi-
cal and clinical significance of NOX may be specific to
NOX isoforms, cell types, and/or a combination of
NOX family members.
Table 5 Comparison of conventional cytology with ROS cytology (follow-up cases with previous history of urothelial
carcinomas)
Conventional cytology ROS cytology
Urothelial carcinoma Positive Suspicious Negative Sensitivity Positive Negative Sensitivity
Low grade(n = 14) 0 5 9 0% 9 5 64%
High grade(n = 14) 8 2 4 57% 14 0 100%
Non-invasive papillary 0 5 8 0% 9 4 64%
(n = 13)
Superficially invasive 3 1 2 50% 5 1 83%
(n = 6)
Deep invasive 1 1 1 33% 3 0 100%
(n = 3)
Carcinoma in situ 3 1 2 50% 6 0 100%
(n = 10)
Specificity Specificity
Negative(n = 34) 0 7 27 79% 1 33 97%
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ROS labeling for urinary cytological diagnosis. The
advantages of urine cytology include high specificity; it
is an established technique and minimal sample proces-
sing is required. In contrast, the high level of expertise
required, significant interobserver variation, and low
sensitivity (especially for low-grade phenotypes) are con-
sidered disadvantages [8,21,22]. At present, several bio-
markers are commercially available: the bladder tumor
antigen (BTA) test measures urine levels of H-related
protein, which is similar to H protein and is secreted in
high levels by tumor cells. The BTA test outperforms
cytology in sensitivity, but its specificity falls below that
of cytology because of false positive results by inflamma-
tory or infectious conditions [23,24]. Nuclear matrix
protein (NMP) 22, a regulator of mitosis, is known to
be increased in malignant urothelium, and quantitative
immunoassay of NMP22 demonstrates superior sensitiv-
ity for bladder cancer compared to urine cytology [25].
However, the specificity is generally lower than that of
urine cytology due to NMP22 dependency on the cut-
off points used [26]. Lately, FISH has attracted consider-
able interest for its high sensitivity (69-96%) and specifi-
city (65-96%) [27]. FISH identifies common alterations
in the chromosomal copy number (chromosomes 3, 7,
and 17) and loss of the 9p21 locus, and is largely unaf-
fected by inflammatory conditions. Recent studies have
shown that FISH could detect subclinical neoplastic
changes [28,29]. However, FISH analysis of urine speci-
mens requires specialized laboratory equipment, expen-
sive reagents, and a high level of expertise; therefore, it
is not suited to high throughput testing. The Interna-
tional and European guideline panels no longer recom-
mend the use of FISH tests, including UroVysion, owing
to inferior specificity and a lack of reliable prospective
testing [1,30]. A fault common to all of these tests is
that they cannot make full use of the merits of urine
cytology. A new diagnostic system that counteracts the
low sensitivity of cytology but retains its high specificity
should be established. Our idea was to introduce label-
ing of ROS produced by urothelial carcinoma cells (but
not by non-malignant cells) to conventional cytology:
ROS-positive cells are theoretically considered to be
malignant cells despite little morphological atypia. The
present study clearly indicates that extraction of ROS-
producing cells using the fluorescent dyes CM-DCFDA
and DHE statistically improves the accuracy of urine
cytology. Moreover, this system was not affected by
post-surgical or therapy-related inflammation or degen-
eration. Sometimes, pathologists and cytologists face the
problem of under- or over-diagnosis, and the number of
suspicious cases that cannot be identified as malignant
or benign increase due to degenerative morphological
changes (for example, the size of malignant cells are
miniaturized, or normal cells are distended and exhibit
atypia). This problem tends to occur especially in fol-
low-up urine samples after surgical or immune therapy.
ROS-C, available in such cases, demonstrated high sen-
sitivity and high specificity. Since the fluorescence level
of ROS-reactive dyes was much higher than that of non-
specific self-fluorescence, there were very few ROS-C
false-positive results in the current study. Inflammatory
cells such as neutrophils and macrophages were labeled
by ROS dyes but were distinguished from epithelial
tumor cells by cytomorphological characteristics. Inter-
and intra-observer variabilities are worth considering for
cytologists who lack experience in handling urine sam-
ples and/or fluorescence microscopy. We are trying to
construct more objective rules to help decide whether
ROS positive cells are malignant–for example, by setting
a threshold of fluorescence intensity.
Conclusion
NOX4 contributes to ROS production and cell survival
in human urothelial carcinoma cells. From the immuno-
profile of NOX4 in normal, dysplastic, and malignant
urothelial cells, NOX4 might be involved in an early
stage of urothelial carcinogenesis and be a potential new
molecular target for bladder cancer therapy. Moreover,
fluorescence labeling of ROS can bring about accurate
pathological and cytological diagnoses of human bladder
cancers. Conventional urine cytology exhibits high speci-
ficity, but unfortunately, low sensitivity, to detect blad-
der cancer. In contrast, ROS labeling methods alone
could exhibit high sensitivity but not high specificity. In
this study, we added ROS labeling methods to conven-
tional cytology and created a new assay system with
high specificity and sensitivity.
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